← Leaderboards
Beth J Hoffman
Origami Therapeutics, Inc.
$804,986
Attributed
$1,109,984
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $502.9K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,109,984 · 2
By mechanism
R43$1,109,984 · 2
Top collaborators
- Natalie Prigozhina2 shared
Most similar at Origami Therapeutics, Inc.
Same institution · by research overlap
- Natalie Prigozhina$304,998
Others in their field
Other Rising Stars on “Drug Kinetics”
- Kevin V Grimes · Stanford University$14,783,804
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
- Alexander Kolykhalov · Emory University$8,116,465
Research focus
Drug KineticsGene ProteinsCystic FibrosisDrug CandidateEffective TherapyFibroblastsClinical TranslationCorpus Striatum StructureDoseAutophagocytosisCellsAnalogAnimal ModelFamilyCell DivisionCell PhysiologyClinical TrialsCognitive DeficitsAtrophicDna DamageBrainCag RepeatAutosomeGenes
Grant awards (3)
Uncovering the molecular target(s) of ORI-113, a potential brain-penetrant small molecule therapeutic for Huntington's disease.$499,988
R43 · FY2025 · NS · contact PI
Characterization of small molecules that lower mutant huntingtin protein as potential therapeutics for Huntingtonâs disease$107,065
R43 · FY2024 · NS · contact PI
Characterization of small molecules that lower mutant huntingtin protein as potential therapeutics for Huntingtonâs disease$502,931
R43 · FY2023 · NS · contact PI